TCT: Impressive Survival Benefit for TAVR in Inoperable Patients at 3 Years

October 24th, 2012

TCT: Impressive Survival Benefit for TAVR in Inoperable Patients at 3 Years

Larry Husten, PHD

At the TCT meeting in Miami, Murat Tuzcu presented the latest findings from the PARTNER B trial comparing transcatheter aortic valve replacement (TAVR) with standard therapy in patients who are not considered eligible for surgical valve replacement. At 3 years, the mortality advantage continued to grow for TAVR over standard therapy.

All-cause mortality at 3 years:

80.9% in the control group versus 54.1% in the TAVR group (HR 0.53, CI 0.41-0.68, p<0.0001)

The difference between the groups has increased from an absolute difference of 20.1% at 1 year (50.8% vs. 30.7%), to 25% at 2 years (68% vs. 43%), to 26.8% at 3 years. Here are the other endpoints reported by Tuzcu:

Rehospitalization at 3 years:

75.7% versus 42.3% (HR 0.39, CI 0.28-0.54, p<0.0001)

Mortality or rehospitalization at 3 years:

93.1% versus 66.3% (HR 0.46, CI 0.36-0.58)

Mortality or stroke at 3 years:

80.9% versus 57.5% (HR 0.60, CI 0.46-0.77, p<0.0001)

The 3-year results, concluded Tuzcu, “continue to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates.” In addition, the results “underscore the importance of patient selection before TAVR and the need for aggressive management of illnesses after TAVR.”

CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

October 24th, 2012